Aasma Shaukat, MD, MPH: The Current State of Colorectal Cancer Screenings


The COVID-19 pandemic has hurt the effort of colorectal cancer screenings.

The recent change in guidance to reduce the recommended age of universal colorectal cancer screenings from 50 to 45 for low-risk individuals might have a drastic impact on early cancer detection.

However, that impact might be minimized by the ongoing COVID-19 pandemic.

One of the biggest issues that has stemmed from the pandemic is a lot of preventative medicine was ignored and forgotten.

And despite a major public awareness campaign to increase colorectal cancer screenings, the pandemic did set things back a bit.

In an interview with HCPLive®, Aasma Shaukat, MD, MPH, Director of Research Outcomes, Division of Gastroenterology and Hepatology, NYU Langone, explained how damaging the pandemic was toward the goal of 80% colorectal cancer screenings for individuals aged 45 years and older.

Shaukat appeared during the 2022 American College of Gastroenterology (ACG) Annual Meeting in Charlotte.

Shaukat also said there remains a need for new research into identifying and categorizing risk factors for colon cancer.

She also said developing a grading system or a score would go a long way toward separating who should be screened at an earlier age and who could wait until they are 45.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.